About Us
Transforming care with advanced radiopharmaceutical innovations and therapies.
OncoBeta is headquartered in Garching, near Munich. We are a privately held medical device and radiochemical company specialising in the development and commercialisation of state-of-the-art, innovative skin cancer therapies utilising cutaneous radioisotope applications.
Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialisation of Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. OncoBeta developed, designed, optimised and refined the customised application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
Rhenium-SCT is MDR-approved in EU (MDR 796214 R000), AEMPS approved Class IIb Medical Device in Spain (PD/2022/6247(D), ARTG-registered in Australia (ARTG Number 400142), Medsafe in New Zealand (230302-WAND-70RGWT), and HAS registration medical device in Singapore (Product Number: MDPR251103W0003). Rhenium-SCT is currently not approved for use in the United States.
Advancing the Future of Precision Oncology
OncoBeta’s vision is to advance the global treatment of cancer through innovative radiotherapeutic solutions that are both effective and accessible. By combining scientific excellence with practical clinical application, we aim to expand the role of targeted radioisotope therapies in modern oncology.
We envision a future where precision treatments can address cancer more effectively while reducing the burden on patients and healthcare systems. Through ongoing research, collaboration, and innovation, OncoBeta strives to help shape a new generation of cancer therapies.
Delivering Innovative Radiotherapeutic Solutions
Our mission is to develop and deliver targeted radiotherapeutic technologies that improve outcomes for patients with cancer. By focusing on therapies that precisely target tumours while minimising impact on surrounding healthy tissue, we seek to provide meaningful treatment options for clinicians and patients.
OncoBeta works closely with healthcare professionals, research partners, and institutions worldwide to translate scientific innovation into practical clinical solutions. Through these collaborations, we aim to support the safe and effective adoption of advanced radioisotope therapies.
Values That Guide Our Work and Partnerships
At OncoBeta, our work is guided by a commitment to scientific integrity, patient-centred innovation, and global collaboration. We believe that meaningful progress in cancer care is achieved through rigorous research, responsible development, and strong partnerships with the clinical and scientific community.
We are dedicated to maintaining the highest standards in quality, safety, and transparency. By fostering a culture of innovation and collaboration, we aim to deliver solutions that make a meaningful difference for patients, healthcare professionals, and healthcare systems worldwide.
Patients drive our objectives to enhance lives through innovative and compassionate healthcare solutions.
Compassion
Innovation
Performance
Respect
Teamwork
Discipline
Integrity
Honesty
Contact form
Contact us
Do you have a question about OncoBeta, our products, or non-melanoma skin cancer therapy with Rhenium-SCT? Talk to us today.